Discovering new treatments for malaria using Plasmodium proteins
Plasmodium Protein Kinase Focused Antimalarials Discovery
['FUNDING_R01'] · UNIVERSITY OF CENTRAL FLORIDA · NIH-10873952
This study is working on creating new medicines to fight malaria by targeting specific proteins in the parasite, with a special focus on helping children who are most affected by the disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CENTRAL FLORIDA (nih funded) |
| Locations | 1 site (ORLANDO, UNITED STATES) |
| Trial ID | NIH-10873952 on ClinicalTrials.gov |
What this research studies
This research aims to develop new antimalarial drugs that target specific proteins in the malaria-causing parasite, Plasmodium. The approach focuses on creating type II kinase inhibitors, which are designed to work effectively against various stages of the parasite's life cycle. By leveraging existing knowledge of drug development, the researchers will synthesize and test these new compounds to see if they can provide better treatment options for malaria, especially in children who are most affected. The study will involve extensive laboratory work to optimize these compounds for safety and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old who are at risk of or suffering from malaria.
Not a fit: Patients who are adults or those who do not have malaria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for malaria, potentially saving thousands of lives, particularly among children.
How similar studies have performed: While the approach of using type II kinase inhibitors is relatively novel in the context of malaria, similar strategies have shown promise in other areas of drug development.
Where this research is happening
ORLANDO, UNITED STATES
- UNIVERSITY OF CENTRAL FLORIDA — ORLANDO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHAKRABARTI, DEBOPAM — UNIVERSITY OF CENTRAL FLORIDA
- Study coordinator: CHAKRABARTI, DEBOPAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.